Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Belimumab is the first biologic approved for children over five years with systemic lupus erythematosus (SLE), but evidence on its long-term efficacy and safety in pediatric populations remains limited. Therefore, we conducted a systematic review and meta-analysis of real-world data to evaluate the long-term outcomes of belimumab in pediatric SLE, with a specific focus on lupus nephritis (LN), and to compare its potential benefits and risks with standard immunotherapy, aiming to provide comprehensive evidence to guide clinical practice.
We searched PubMed, Embase, the Cochrane Library, and Wanfang through September 2025 for studies reporting 6- and 12-month outcomes of belimumab in pediatric SLE. Pooled proportions of dichotomous outcomes (Lupus low disease activity state, flare, adverse events, and complete remission of LN) were calculated using the logit method, and risk ratios (RRs) were applied to compare proportions between the belimumab and standard immunotherapy groups in double-arm studies. For continuous outcomes (Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score change and glucocorticoid dose reduction), pooled means were estimated under a random-effects model, with group comparisons expressed as mean differences (MDs).
Sixteen cohort and clinical trial studies were included in the meta-analysis. In pediatric SLE, belimumab reduced SLEDAI scores by 10.16 (95% CI, 5.72–14.60) at 6 months and 17.71 (95% CI, 4.35–31.08) at 12 months. Lupus low disease activity state proportions were 79% (95% CI, 68%–87%) at 12 months, whereas at 6 months, it was 42% (95% CI, 15%–72%) based on a single study. Daily glucocorticoid dose decreased by 19.88 mg/day (95% CI, 6.58–33.18) at 6 months and 11.84 mg/day (95% CI, -7.98 to 31.65) at 12 months. The complete remission of LN was achieved in 80% (95% CI, 40%–96%) at 6 months and 94% (95% CI, 82%–98%) at 12 months. The 12-month flare incidence was 7% (95% CI, 2%–22%). Adverse event rates were 12% (95% CI, 6%–21%) at 6 months and 46% (95% CI, 18%–77%) at 12 months. Compared with standard immunotherapy, belimumab yielded greater SLEDAI reduction (MD, 2.86; 95% CI, 1.48–4.24; p<0.001), fewer adverse events (RR, 0.37; 95% CI, 0.19 – 0.73; p=0.004), and higher LN remission (RR, 1.26; 95% CI, 1.03–1.55; p=0.03) at 6 months, and a lower flare risk at 12 months (RR, 0.44; 95% CI, 0.20–0.88; p=0.02), with no other significant differences at 12 months.
In pediatric SLE, add-on belimumab improves disease control and safety at 6 months and reduces flare risk at 12 months compared with standard immunotherapy.
